Scarica l'app Stockscreener
127.80
0.12%
-0.15
Dopo l'orario di chiusura:
127.75
-0.05
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$127.95
Aprire:
$127.08
Volume 24 ore:
682.07K
Relative Volume:
0.40
Capitalizzazione di mercato:
$19.53B
Reddito:
$4.28B
Utile/perdita netta:
$1.26B
Rapporto P/E:
16.19
EPS:
7.8957
Flusso di cassa netto:
$943.00M
1 W Prestazione:
-1.55%
1M Prestazione:
+9.36%
6M Prestazione:
+53.68%
1 anno Prestazione:
-10.32%
Intervallo 1D:
$124.27
$128.28
Intervallo di 1 settimana:
$124.27
$132.15
Portata 52W:
$68.70
$153.06
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Confronta ILMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
127.80 | 19.55B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
575.24 | 218.08B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
227.13 | 161.37B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
717.35 | 57.97B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.32 | 42.25B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
224.92 | 38.70B | 15.90B | 1.28B | 2.21B | 7.2842 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Epigenetics Market size to reach $8.63 Billion by 2035 | Key - openPR.com
Will Illumina Inc. (ILU) stock keep high P E multiplesTrade Signal Summary & Safe Capital Allocation Plans - Newser
Can Illumina Inc. (ILU) stock sustain revenue momentumJuly 2025 Setups & Entry Point Confirmation Signals - Newser
How Illumina Inc. (ILU) stock reacts to fiscal policiesJuly 2025 Catalysts & Daily Risk Controlled Trade Plans - Newser
Why Illumina Inc. (ILU) stock fits value portfoliosOil Prices & Fast Exit/Entry Strategy Plans - Newser
Genetic testing transformed her cancer care—and her family tree - Illumina
Why global investors buy Illumina Inc. (ILU) stockJuly 2025 Sentiment & Verified Momentum Watchlists - Newser
Tumor Transcriptomics Research Report 2025: An $8.71 Billion Market by 2030, Driven by Rising Global Cancer Prevalence and Advancements in Genomic Sequencing Technologies - GlobeNewswire Inc.
Illumina’s China Setback Leaves A Discounted Genomics Leader - Finimize
Illumina, Inc. Stock (ILMN) Opinions on Strategic Growth and Market Expansion - Quiver Quantitative
Will Illumina Inc. stock outperform international peersTrade Risk Report & Free Fast Entry Momentum Trade Alerts - BỘ NỘI VỤ
Is Illumina Inc. stock undervalued vs historical averagesTrend Reversal & Fast Moving Trade Plans - BỘ NỘI VỤ
DNA Sequencing Market to Hit US$ 51.31 Billion by 2034 at 14.9% - openPR.com
When a worldwide community comes together - Illumina
Illumina completes $500 million public offering of 4.750% notes due 2030 - Investing.com Nigeria
Illumina completes $500 million public offering of 4.750% notes due 2030 By Investing.com - Investing.com South Africa
Illumina Completes $500M Notes Offering for Expansion - TipRanks
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
How Will Analyst Reactions to ILMN’s Wolfe Conference Pitch Shape Confidence in Its Turnaround Plan? - simplywall.st
Nucleic Acid Isolation & Purification Market to Reach US$ 9.77 - openPR.com
Functional Genomics Market Set to Boom: Strategic Insights - openPR.com
The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - TradingView
Genomic Biomarker Market By Top Companies Illumina,Thermo - openPR.com
Is Illumina Inc. (ILU) stock positioned for digital growth eraSwing Trade & Daily Price Action Insights - newser.com
Is Illumina Inc. forming a bottoming baseRate Cut & Real-Time Volume Analysis - newser.com
Committed to accelerating precision medicine in China - Illumina
Does Illumina’s 20% Surge Signal a Reversal After GRAIL Divestiture News? - Yahoo Finance
Will Illumina Inc. (ILU) stock justify high valuationJuly 2025 Recap & Technical Buy Zone Confirmations - newser.com
Will Illumina Inc. (ILU) stock deliver stable dividends2025 Retail Activity & Safe Capital Growth Tips - newser.com
Will Illumina Inc. (ILU) stock test record highs in 2025Jobs Report & Risk Controlled Swing Alerts - newser.com
Real time pattern detection on Illumina Inc. stockRecession Risk & Daily Profit Maximizing Tips - newser.com
Why analysts maintain buy rating on Illumina Inc. (ILU) stockEarnings Beat & Risk Controlled Swing Trade Alerts - newser.com
What moving averages say about Illumina Inc.2025 Market Outlook & Smart Swing Trading Alerts - newser.com
Is Illumina Inc. (ILU) stock inflation resilient2025 Stock Rankings & AI Forecasted Stock Moves - newser.com
Transcript : Illumina, Inc. Presents at 7th Annual Wolfe Research Healthcare Conference, Nov-19-2025 09 - MarketScreener
Candlestick signals on Illumina Inc. stock todayIPO Watch & Consistent Growth Stock Picks - newser.com
Illumina at Wolfe Research Conference: Strategic Growth Amid Challenges - Investing.com India
Illumina at Wolfe Research Conference: Strategic Growth Amid Challenges By Investing.com - Investing.com Canada
3 Reasons to Sell ILMN and 1 Stock to Buy Instead - Finviz
Published on: 2025-11-19 04:40:33 - newser.com
Published on: 2025-11-18 23:37:24 - newser.com
Illumina sells GRAIL shares worth $79.85 million By Investing.com - Investing.com South Africa
Illumina sells GRAIL shares worth $79.85 million - Investing.com
Tackling antimicrobial resistance, one genome at a time - Illumina
Illumina Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):